Lipitor II
Executive Summary
After hosting delegations of licensing hopefuls for its phase III Cox-2 inhibitor, Searle chose Pfizer Inc., the industry's most aggressive and probably most successful co-promoter. Searle's next likely co-promotion announcements will concern its phase IIb/IIIa platelet inhibitors.
You may also be interested in...
Pfizer's Lipitor Sees Big Boost From Medicare
Pfizer is discounting its blockbuster brand Lipitor more aggressively. But, thanks to the economics of Medicare Part D, the product is still benefiting from a big net price increase in 2006. Lipitor's performance is some much needed good news for Pfizer--and maybe even better news for the industry as a whole.
US FDA And NIST Form Partnership To Boost Advanced Manufacturing Techniques
The US FDA and NIST have agreed to help industry modernize and update pharmaceutical manufacturing methods and to improve supply chain resilience.
Medtronic Looks To Adaptive DBS To Advance Treatment Of Parkinson’s Disease
Medtronic is sponsoring a trial to evaluate its adaptive deep brain stimulation technology, a unique feature of the Percept PC device for treating Parkinson’s disease.
Need a specific report? 1000+ reports available
Buy Reports